NEWS
SHL Medical | 2019.10

SHL to participate in 2019 PDA Universe of Pre-filled Syringes and Injection Devices

SHL is set to join one of the Parenteral Drug Association’s (PDA) key annual conferences, the Universe of Pre-filled Syringes and Injection Devices. For the first time since its inception, the PDA event will be hosted in Gothenburg, Sweden. SHL founder and President Roger Samuelsson grew up in the Gothenburg area during his formative years, later on establishing the global company it is today. Sweden is a key strategic location in which SHL has a design center and where talented designers and engineers develop breakthrough drug delivery solutions for pharmaceutical clients.

This year’s agenda highlights an important goal of continuous research and innovation in the medical device industry – to advance drug delivery systems that help improve patient quality of life.

Now in its 30th year, SHL has significantly helped pharmaceutical companies redefine how patients self-inject drugs outside hospitals. Over the years, SHL has been inciting changes and expanding its scope of vision, and this has helped shape the SHL perspective towards the development of its line of products.

Earlier this year, a combination product for type II diabetes equipped with SHL’s Needle Isolation Technology (NIT®) received the Medical Design Excellence Awards. NIT® is SHL’s proprietary safety solution for cartridge-based auto-injectors. NIT® features a pre-installed needle that is permanently hidden throughout the injection process, thus eliminating the need for patients to manually attach the needle before each injection. SHL offers a full range of solutions for all types of subcutaneous and intramuscular formulations for self-injections including Maggie®, an injector built with NIT® able to deliver highly viscous formulations and accommodate fill volumes up to 3mL.

Magnus Fastmarken, SHL Global Marketing Director said, “For more than 20 years, the SHL perspective is what has kept us at the forefront of the auto-injector industry, delivering drug-device solutions to pharmaceutical companies and their patients. The opening of our brand new manufacturing facility in Taoyuan, Taiwan is an important milestone to meet future customer needs and set a new standard in manufacturing.”

SHL has continuously established an array of in-house manufacturing and testing capabilities. This gives SHL a unique position – having full control of all processes in order to ensure that project requirements are always met. Part of this year’s two-day agenda is a talk by SHL experts Gilbert Fluetsch and Lucy Chung titled, “Modularizing Assembly and Testing Equipment for Auto and Pen Injectors.” QuiO Technologies co-founder Alexander Dahmani will give a presentation titled, “Software and Services to Transform Drugs into Disease Management Solutions.” QuiO Technologies is SHL’s official partner in connected therapeutics.

The PDA Europe conference will be held between October 22 to 23 at the Swedish Exhibition and Congress Center in Gothenburg, Sweden.

關於瑞健

瑞健集團為領航全球先進藥物輸送系統產業的設計、研發、及製造龍頭。其事業據點涵蓋位於瑞士、瑞典、美國及台灣的現代化設計中心以及設立於亞洲的先進製造廠房。 瑞健主要客戶為世界知名藥廠以及生技公司,提供如自動化注射器,筆型注射器以及吸入器等高科技產品。瑞健持續投資於研發製造為開發新型高科技藥物輸送系統以符合市場趨勢,其中包括使用步驟簡化、注射器精密化、拋棄式/複用式多重選擇、劑量彈性化以及藥劑濃稠度之配合等。

瑞健目前全球已有超過 4,000 名員工,主要分為以下事業群:

SHL Medical 主要為製藥和生技企業設計、研發、及製造高科技藥物傳輸系統,也提供終端組裝、醫材標籤及包裝相關服務

SHL Healthcare 從事居家及醫院護理器材之研發製造

SHL Technologies 提供醫療科技及工業設備之 OEM 製造與相關服務

如欲更深入了解瑞健集團,請至公司網站 www.shl.group.

瑞健媒體聯絡人

info@shl-group.com